down arrow

Organon & Co.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US68622V1061
USD
6.84
-0.15 (-2.15%)

Dec 18

NYS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

6.757.04

52 Week

6.1817.23
Valuation
Technical
Day's Volume

CASH

4.73 M

Shareholding (Mar 2025)

FII

16.40%

Held by 252 FIIs

DII

27.37%

Held by 87 DIIs

Promoter

0.01%

How big is Organon & Co.?

22-Jun-2025

As of Jun 18, Organon & Co. has a market capitalization of 2,560.57 million, with net sales of 6,294.00 million and a net profit of 750.00 million over the latest four quarters.

As of Jun 18, Organon & Co. has a market capitalization of 2,560.57 million, categorizing it as a Small Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 6,294.00 million, while the sum of net profit for the same period is 750.00 million.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds of 472.00 million and total assets amounting to 13,101.00 million.

Read More

What does Organon & Co. do?

22-Jun-2025

Organon & Co. is a small-cap pharmaceutical and biotechnology company with recent net sales of $1.513 billion and a net profit of $87 million. Key metrics include a P/E ratio of 3.00, a dividend yield of 0.20%, and a market cap of $2.56 billion.

Overview: <BR>Organon & Co. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a small-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 1,513 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 87 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 2,560.57 Million (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 3.00 <BR>Dividend Yield: 0.20% <BR>Debt Equity: 15.51 <BR>Return on Equity: 163.16% <BR>Price to Book: 4.72 <BR><BR>Contact Details: <BR>Registrar Address: Not available.

Read More

Is Organon & Co. overvalued or undervalued?

20-Sep-2025

As of May 2, 2024, Organon & Co. is considered very attractive for investment due to its undervaluation, reflected in a P/E ratio of 3 and an EV to EBITDA ratio of 6.41, despite a year-to-date return of -27.28%.

As of 2 May 2024, the valuation grade for Organon & Co. moved from risky to very attractive, indicating a significant improvement in its investment appeal. The company appears undervalued, supported by a P/E ratio of 3, an EV to EBITDA ratio of 6.41, and a Price to Book Value of 4.59. In comparison, Exelixis, Inc. has a P/E ratio of 15.81 and an EV to EBITDA of 11.97, while Alkermes Plc shows a P/E of 13.77 and an EV to EBITDA of 9.41, highlighting Organon’s relative undervaluation within the industry.<BR><BR>Despite recent struggles, with a year-to-date return of -27.28% compared to the S&P 500's 12.22%, the substantial drop in Organon's stock price may present a buying opportunity given its attractive valuation metrics.

Read More

Is Organon & Co. technically bullish or bearish?

23-Sep-2025

As of September 19, 2025, Organon & Co. is in a mildly bearish trend, indicated by daily moving averages and bearish signals from the monthly MACD and KST, while underperforming the S&P 500 with a return of -45.77% compared to its 16.64%.

As of 19 September 2025, the technical trend for Organon & Co. has changed from sideways to mildly bearish. The current stance is bearish, primarily driven by the daily moving averages indicating a mildly bearish trend, alongside the monthly MACD and KST both showing bearish signals. The weekly Bollinger Bands are bullish, but this is offset by the overall bearish indicators on the monthly timeframe. <BR><BR>In terms of performance, Organon has underperformed the S&P 500 significantly over the year, with a return of -45.77% compared to the S&P 500's 16.64%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Company has a low Debt to Equity ratio (avg) at times

 
2

Healthy long term growth as Net Sales has grown by an annual rate of 13.72% and Operating profit at -3.44%

 
3

Negative results in Jun 25

4

With ROE of 163.16%, it has a very attractive valuation with a 4.59 Price to Book Value

5

Below par performance in long term as well as near term

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 2,722 Million (Small Cap)

stock-summary
P/E

3.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.38%

stock-summary
Debt Equity

11.32

stock-summary
Return on Equity

111.78%

stock-summary
Price to Book

3.71

Revenue and Profits:
Net Sales:
1,594 Million
(Quarterly Results - Jun 2025)
Net Profit:
145 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-36.96%
0%
-36.96%
6 Months
-30.77%
0%
-30.77%
1 Year
-52.86%
0%
-52.86%
2 Years
-47.87%
0%
-47.87%
3 Years
-75.07%
0%
-75.07%
4 Years
-77.34%
0%
-77.34%
5 Years
0%
0%
0.0%

Organon & Co. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Organon & Co. Stock Plummets to New 52-Week Low of $6.18

Organon & Co. Stock Plummets to New 52-Week Low of $6.18

Organon & Co. has hit a new 52-week low, reflecting a challenging year with a significant stock price decline. The company has a market capitalization of USD 2,722 million, a low P/E ratio, and a high return on equity, but faces operational difficulties and increased costs.

Read More
Organon & Co. Hits New 52-Week Low at USD 6.32 Amid Decline

Organon & Co. Hits New 52-Week Low at USD 6.32 Amid Decline

Organon & Co. has reached a new 52-week low, reflecting a challenging year with a significant stock price decline. The company has a market capitalization of USD 2,722 million, a low P/E ratio, and reports a decrease in net profit alongside rising raw material costs, indicating ongoing financial struggles.

Read More
Organon & Co. Experiences Revision in Stock Evaluation Amid Market Dynamics

Organon & Co. Experiences Revision in Stock Evaluation Amid Market Dynamics

Organon & Co., a small-cap pharmaceutical company, is experiencing stock price fluctuations, currently at $10.57. The company has faced significant challenges, with a year-over-year return of -45.77%, underperforming the S&P 500. Technical indicators present a mixed outlook, reflecting varied momentum in the market.

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
13.72%
EBIT Growth (5y)
-3.44%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
3.73
Net Debt to Equity (avg)
15.51
Sales to Capital Employed (avg)
0.71
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
33.59%
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
25.39%
ROE (avg)
858.56%
Valuation key factors
Factor
Value
P/E Ratio
3
Industry P/E
Price to Book Value
4.59
EV to EBIT
7.75
EV to EBITDA
6.41
EV to Capital Employed
1.22
EV to Sales
1.73
PEG Ratio
NA
Dividend Yield
0.21%
ROCE (Latest)
15.70%
ROE (Latest)
163.16%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
Bullish
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 128 Schemes (56.13%)

Foreign Institutions

Held by 252 Foreign Institutions (16.4%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 5.35% vs -4.96% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 66.67% vs -20.18% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,594.00",
          "val2": "1,513.00",
          "chgp": "5.35%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "415.00",
          "val2": "409.00",
          "chgp": "1.47%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "132.00",
          "val2": "128.00",
          "chgp": "3.12%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "4.00",
          "val2": "-97.00",
          "chgp": "104.12%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "145.00",
          "val2": "87.00",
          "chgp": "66.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "204.50%",
          "val2": "214.80%",
          "chgp": "-1.03%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 2.24% vs 1.44% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -15.54% vs 11.56% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "6,403.00",
          "val2": "6,263.00",
          "chgp": "2.24%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1,775.00",
          "val2": "1,563.00",
          "chgp": "13.56%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "529.00",
          "val2": "527.00",
          "chgp": "0.38%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-93.00",
          "val2": "-70.00",
          "chgp": "-32.86%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "864.00",
          "val2": "1,023.00",
          "chgp": "-15.54%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "234.00%",
          "val2": "211.90%",
          "chgp": "2.21%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
1,594.00
1,513.00
5.35%
Operating Profit (PBDIT) excl Other Income
415.00
409.00
1.47%
Interest
132.00
128.00
3.12%
Exceptional Items
4.00
-97.00
104.12%
Consolidate Net Profit
145.00
87.00
66.67%
Operating Profit Margin (Excl OI)
204.50%
214.80%
-1.03%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 5.35% vs -4.96% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 66.67% vs -20.18% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
6,403.00
6,263.00
2.24%
Operating Profit (PBDIT) excl Other Income
1,775.00
1,563.00
13.56%
Interest
529.00
527.00
0.38%
Exceptional Items
-93.00
-70.00
-32.86%
Consolidate Net Profit
864.00
1,023.00
-15.54%
Operating Profit Margin (Excl OI)
234.00%
211.90%
2.21%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 2.24% vs 1.44% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -15.54% vs 11.56% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Organon & Co. stock-summary
stock-summary
Organon & Co.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."